doripenem has been researched along with meropenem in 128 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 29 (22.66) | 29.6817 |
2010's | 81 (63.28) | 24.3611 |
2020's | 18 (14.06) | 2.80 |
Authors | Studies |
---|---|
Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
Bonomo, RA; Decker, BK; Hujer, AM; Hujer, KM; Perez, F; Rather, PN | 1 |
Appelbaum, PC; Credito, KL; Ednie, LM | 1 |
Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA | 1 |
Bush, K; Davies, TA; Flamm, RK; Shang, W | 1 |
Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
Brown, NP; Pillar, CM; Sahm, DF; Shah, D; Torres, MK | 1 |
Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
Goto, T; Ichiishi, T; Mikamo, H; Nakao, K; Tanaka, K; Watanabe, K; Yamagishi, Y | 1 |
Bell, JM; Castanheira, M; Jones, RN; Mathai, D; Turnidge, JD | 1 |
Thamlikitkul, V; Trakulsomboon, S | 1 |
Bauernfeind, A; Keuleyan, E; Markova, B; Markovska, R; Queenan, AM; Schneider, I | 1 |
Bulik, CC; Crandon, JL; Nicolau, DP | 1 |
Bush, K; Flamm, R; Queenan, AM; Shang, W | 1 |
Aquino, EE; León, CF; Otero, DM; Robledo, IE; Santana, JL; Santé, MI; Vázquez, GJ | 1 |
Flamm, R; Friedland, I; Kaniga, K; Lee, M; Redman, R; Tong, SY | 1 |
Choi, JY; Ko, KS; Lee, MY; Park, YK; Peck, KR; Rhee, JY; Shin, JY; Song, JH | 1 |
Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M | 1 |
Bulik, CC; Nicolau, DP | 1 |
Bernabeu, S; Nordmann, P; Poirel, L; Revathi, G | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Arthur, M; Braud, E; Compain, F; Dubée, V; Etheve-Quelquejeu, M; Fonvielle, M; Hugonnet, JE; Iannazzo, L; Mainardi, JL; Soroka, D; Triboulet, S | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Fernando, DM; Gorityala, BK; Goswami, S; Guchhait, G; Kumar, A; Schweizer, F; Zhanel, GG | 1 |
Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
Bermingham, A; Blais, J; Capka, V; Cariaga, T; Casarez, A; Colvin, R; Dean, CR; Fekete, A; Gong, W; Growcott, E; Guo, H; Jones, AK; Li, C; Li, F; Lin, X; Lindvall, M; Lopez, S; McKenney, D; Metzger, L; Moser, HE; Prathapam, R; Rasper, D; Reck, F; Rudewicz, P; Sethuraman, V; Shaul, J; Shen, X; Simmons, RL; Tang, D; Tashiro, K; Tjandra, M; Turner, N; Uehara, T; Vitt, C; Whitebread, S; Yifru, A; Zang, X; Zhu, Q | 1 |
Bethel, CR; Bonomo, RA; Cmolik, A; Domitrovic, TN; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BM; Kumar, V; Logan, LK; Marshall, EK; Marshall, SH; Nguyen, H; O'Shea, M; Papp-Wallace, KM; Perez, F; Plummer, MS; Rudin, SD; Spencer, EJ; van den Akker, F; van Duin, D | 1 |
Bethel, CR; Bonomo, RA; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Kumar, V; Marshall, SH; Papp-Wallace, KM; Perez, F; Plummer, MS; Spencer, EJ; van den Akker, F; van Duin, D | 1 |
Nagayama, A; Nomura, S | 1 |
Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
Abe, K; Arai, T; Hasebe, N; Horiuchi, M; Kimura, M; Tokumura, M | 1 |
Fujimoto, S; Ike, Y; Sakyo, S; Tanimoto, K; Tomita, H | 1 |
Dilay, L; Hoban, DJ; Karlowsky, JA; Noreddin, AM; Rubinstein, E; Thomson, K; Wiebe, R; Zhanel, GG | 1 |
Katsube, T; Yamano, Y; Yano, Y | 1 |
Lister, PD | 1 |
Nicolau, DP | 1 |
Joseph, J; Rodvold, KA | 1 |
Kobayashi, Y; Sumitani, Y | 1 |
Friedland, I; Jasovich, A; Jiang, J; Kaniga, K; Lucasti, C; Umeh, O | 1 |
Alba, V; Marti, S; Sánchez-Céspedes, J; Vila, J | 1 |
Porath, AD | 1 |
Sahm, D | 1 |
Kawamura, H; Matsumoto, K; Miyanohara, H; Nishi, J; Orita, M; Shigemi, A; Shimodozono, Y; Takeda, Y; Tokuda, K; Yaji, K; Yamada, K | 1 |
Berthoin, K; Carryn, S; Le Duff, CS; Marchand-Brynaert, J; Tulkens, PM | 1 |
Esterly, JS; Malczynski, M; Qi, C; Scheetz, MH | 1 |
Crandon, JL; Keel, RA; Nicolau, DP; Sutherland, CA | 1 |
Cantón, R; García, A; Gimeno, C; Gobernado, M | 1 |
Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
Cassettari, M; Chongthaleong, A; Christiansen, KJ; Cooper, D; Flamm, R; Garcia, J; Hsu, L; Ip, M; Ker, HB; Kiratisin, P; Mendoza, M; Morrissey, I; Okolo, P; Quintana, A; Redjeki, IS | 1 |
Ko, KS; Lee, H; Peck, KR; Song, JH | 1 |
Araki, N; Kamihira, S; Kohno, S; Morinaga, Y; Yamada, K; Yamada, Y; Yanagihara, K | 1 |
Abbanat, D; Barron, A; Bunting, RA; Fernandez, J; Flamm, RK; Hall, L; Hilliard, JJ; Lynch, AS; Melton, JL; Ward, CK | 1 |
Gomersall, C; Kuti, JL; Kwa, A; Montakantikul, P; Nicolau, DP; Roberts, JA | 1 |
Chiang, T; Colon-Urban, R; Eng, RH; Gomez, E; Huang, DB; Mariano, N; Urban, C | 1 |
Flamm, RK; Korten, V; Laeuffer, JM; Morrissey, I; Mutters, R; Nordmann, P; Picazo, JJ; Quintana, A; Seak, JC | 1 |
Apisarnthanarak, A; Apisarnthanarak, P; Kiratisin, P; Mundy, LM | 1 |
Goessens, WH; Mol, M; Pitout, JD; van der Bij, AK; van Westreenen, M | 1 |
Akalın, H; Akova, M; Arman, D; Aygen, B; Başaran, S; Bayramoğlu, G; Dizbay, M; Dokuzoğuz, B; Eraksoy, H; Esener, H; Hasçelik, G; Köksal, I; Korten, V; Oğünç, D; Sınırtaş, M; Söyletir, G; Sümerkan, B; Tünger, A; Ulusoy, S; Yalçın, AN | 1 |
Cabot, G; Cantón, R; del Campo, R; García-Castillo, M; Juan, C; Mulet, X; Oliver, A; Riera, E | 1 |
Amsler, K; Davies, TA; Flamm, RK; He, W; Lynch, AS; Marie Queenan, A; Morrow, BJ; Pillar, C; Shang, W | 1 |
Akers, KS; Beckius, ML; Calvano, T; Hospenthal, DR; Markelz, AE; Mende, K; Murray, CK; Yu, X; Zera, WC | 1 |
Baek, JY; Kang, CI; Ko, KS; Peck, KR; Song, JH | 1 |
Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
Hagihara, M; Kuti, JL; Nicolau, DP | 1 |
Decker-Burgard, S; Laeuffer, J; Morrissey, I; Mutters, R; Seifert, H; Valenza, G | 1 |
Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
Chen, CC; Cheng, KC; Chiang, SR; Chiu, YH; Chuang, YC; Ko, WC; Ku, YH; Tang, HJ; Zhang, CC | 1 |
Ichikawa, M; Kurokawa, M; Nannya, Y; Narukawa, K; Toya, T | 1 |
Dundar, D; Kasap, M; Kolayli, F; Torol, S; Vahaboglu, H | 1 |
Chang, SC; Dong, SX; Wang, JT | 1 |
Keel, RA; Kiratisin, P; Nicolau, DP | 1 |
Colakoğlu, S; Durmaz, S; Ekincioğlu, P; Perçin, D | 1 |
Adamski, P; Bulanda, M; Drzewiecki, A; Sodo, A; Talaga, K | 1 |
Dantier, C; Desarbre, E; Gebhardt, K; Hofer, B; Page, MG; Schmitt-Hoffmann, A | 1 |
Kaniga, K; Lee, M; Redman, R; Rice, DA | 1 |
Baziaka, F; Galani, L; Giamarellou, H; Karaiskos, I | 1 |
Kemper, AL; Young, DC; Zobell, JT | 1 |
Goff, DA; Nicolau, DP | 1 |
Guzek, A; Korzeniewski, K; Nitsch-Osuch, A; Prokop, E; Rybicki, Z | 1 |
Kirikae, T; Miyoshi-Akiyama, T; Shimada, K; Shimojima, M; Tada, T | 1 |
Arthur, M; Cordillot, M; Dubée, V; Dubost, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB | 1 |
Aubry, A; Bréchot, N; Brisson, H; Brossier, F; Chastre, J; Combes, A; Jarlier, V; Lu, Q; Luyt, CE; Micaelo, M; Rouby, JJ; Trouillet, JL | 1 |
Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
Abbasi, SA; Day, KM; Paterson, DL; Perry, JD; Raza, MW; Sartor, AL; Sidjabat, HE | 1 |
Abe, J; Fujita, A; Hino, M; Hirose, A; Kakeya, H; Kaneko, Y; Nakaie, K; Nakamura, Y; Okada, Y; Takizawa, E; Yamada, K | 1 |
Black, DJ; Frase, H; Smith, CA; Stewart, NK; Vakulenko, SB | 1 |
Liu, W; Miao, J; Qin, YP; Shu, SQ; Wang, Y; Zhang, L; Zheng, J | 1 |
Ikawa, K; Ishihara, N; Isobe, T; Karino, F; Miura, K; Morikawa, N; Naora, K; Nishimura, N; Tamaki, H | 1 |
Carlson, EE; Kocaoglu, O; Tsui, HC; Winkler, ME | 1 |
Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U | 1 |
Anh, NQ; Kirikae, T; Miyoshi-Akiyama, T; Nhung, PH; Ohmagari, N; Phuong, DM; Shimada, K; Tada, T | 1 |
Barnett, AG; Diab, S; Fraser, JF; Fung, YL; Roberts, JA; Shekar, K; Wallis, SC | 1 |
Asık, G; Atasoy, AR; Aykan, SB; Ciftci, IH; Karakece, E; Terzi, HA | 1 |
Ji, S; Li, C; Li, S; Liang, X; Zhang, F; Zhu, Y | 1 |
Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Maitte, A; Potel, G | 1 |
Arakawa, Y; Jin, W; Kimura, K; Kurosaki, H; Mori, S; Wachino, J; Yamaguchi, Y | 1 |
Abdollahi, A; Aliramezani, A; Boroumand, MA; Douraghi, M; Ghalavand, Z; Ghourchian, S; Mohammadzadeh, M; Nateghi Rostami, M; Rahbar, M; Zeraati, H | 1 |
Aubry, A; Chastre, J; Crandon, JL; Luyt, CE; Nicolau, DP | 1 |
Hu, YF; Liu, CP; Shih, SC; Wang, NY | 1 |
Ajao, AO; Albrecht, JS; Furuno, JP; Harris, AD; Johnson, JK; Pineles, LL; Robinson, GL; Thom, KA; Zhao, L | 1 |
Cancelli, F; Castaldi, D; Ciardi, MR; Cipolla, A; D'Abramo, A; D'Agostino, C; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Scorzolini, L; Vullo, V | 1 |
Aubry, A; Bréchot, N; Brossier, F; Jarlier, V; Lu, Q; Luyt, CE; Micaëlo, M; Monsel, A | 1 |
Antunes, NT; Smith, CA; Stewart, NK; Toth, M; Vakulenko, SB | 1 |
Aoki, Y; Fujishima, Y; Hanamura, I; Ishida, Y; Ito, S; Kowata, S; Mine, T; Oyake, T; Sugawara, N; Takemasa-Fujisawa, Y; Tsukushi, Y | 1 |
Abdalhamid, B; Fowler, RC; Hanson, ND; Harrison, LB; Selmecki, A | 1 |
Chuang, YC; Liu, WD; Sheng, WH; Shih, MC; Wang, JT | 1 |
Smith, CA; Stewart, NK; Toth, M; Vakulenko, SB | 1 |
Fu, L; Li, H; Li, X; Liu, J; Luo, S; Wan, Z; Wang, Y; Wu, X; Xie, X; Zhao, Z | 1 |
Ide, N; Sato, S; Sawaguchi, K | 1 |
Bruno, CJ; Kollef, MH; Réa-Neto, Á; Rhee, EG; Wunderink, RG | 1 |
Lai, CC; Tang, HJ | 1 |
Pliska, NN | 1 |
Ikebuchi, K; Imai, K; Kawamura, T; Kodana, M; Maeda, T; Maesaki, S; Mitsutake, K; Murakami, T; Ogane, K; Onodera, A; Sakai, J; Takeuchi, S; Tarumoto, N | 1 |
Jeyakanthan, J; Lopes, BS; Ramachandran, B | 1 |
Allison, N; Crisostomo, C; Lynch, B; Padilla, M; Quach-Cu, J; Reinke, RA | 1 |
Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 2 |
Chang, H; Lee, CM; Lee, MC; Lu, CH; Sun, FJ; Wu, AY | 1 |
Baccaro, M; Bakker, W; Murali, A; Rietjens, IMCM; van Ravenzwaay, B; Wang, J; Zhang, N; Zheng, W | 1 |
Ishaq, M; Zahra, N; Zeshan, B | 1 |
Dargahi, Z; Etemad, A; Ghasemian, E; Hashemian, M; Kaviar, VH; Lohrasbi, A; Saadh, MJ | 1 |
George Priya Doss, C; Gopikrishnan, M | 1 |
Asai, Y; Ooi, H; Sato, Y | 1 |
Hsueh, PR; Ko, WC; Lee, YL | 1 |
8 review(s) available for doripenem and meropenem
Article | Year |
---|---|
Global challenge of multidrug-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparative review of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Thienamycins | 2007 |
Carbapenems in the USA: focus on doripenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins; United States | 2007 |
Carbapenems: a potent class of antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Molecular Structure; Structure-Activity Relationship; Thienamycins | 2008 |
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Patient Selection; Pneumonia, Bacterial; Respiratory Tract Infections; Severity of Illness Index; Thienamycins; Treatment Outcome | 2008 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
6 trial(s) available for doripenem and meropenem
Article | Year |
---|---|
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins | 2008 |
A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Female; Fever; Hematologic Neoplasms; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Risk Factors; Thienamycins; Treatment Outcome | 2012 |
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem; Intraabdominal Infections; Male; Meropenem; Ofloxacin; Pneumonia; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Gram-Negative Bacteria; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity; Thienamycins | 2014 |
Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Thienamycins | 2014 |
Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chemotherapy-Induced Febrile Neutropenia; Doripenem; Female; Fever; Humans; Leukemia; Male; Meropenem; Middle Aged; Myelodysplastic Syndromes; Prospective Studies | 2019 |
114 other study(ies) available for doripenem and meropenem
Article | Year |
---|---|
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Colony Count, Microbial; Doripenem; Humans; Microbial Sensitivity Tests | 2008 |
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Diabetic Foot; Doripenem; Humans; Microbial Sensitivity Tests | 2008 |
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Carbapenems; Doripenem; Escherichia coli; Escherichia coli Proteins; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Pseudomonas aeruginosa | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; United States | 2008 |
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Doripenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2009 |
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity Tests; Molecular Sequence Data; Prevalence; Pseudomonas aeruginosa; Ribotyping | 2009 |
In vitro activity of doripenem against Burkholderia pseudomallei.
Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Carbapenems; Doripenem; Microbial Sensitivity Tests | 2009 |
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bulgaria; Cefepime; Cefotaxime; Ceftazidime; Cephalosporins; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data | 2009 |
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Female; Humans; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Carbapenems; Doripenem; Enzyme Inhibitors; Hydrolysis; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2010 |
Detection of KPC in Acinetobacter spp. in Puerto Rico.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; beta-Lactam Resistance; beta-Lactamases; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance; Puerto Rico | 2010 |
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Ciprofloxacin; Clinical Trials, Phase III as Topic; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Global Health; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2010 |
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Male; Renal Dialysis; Republic of Korea | 2010 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam | 2010 |
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Humans; Immunocompetence; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Thigh | 2010 |
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Kenya; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Polymerase Chain Reaction | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Humans; Hydrolysis; Kinetics; Mycobacterium tuberculosis; Peptidyl Transferases; Tuberculosis | 2016 |
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; CHO Cells; Cricetulus; Drug Stability; Escherichia coli; Female; Humans; Meropenem; Mice; Microbial Sensitivity Tests; Molecular Structure; Monobactams; Pseudomonas aeruginosa; Receptors, GABA-A; Seizures; Structure-Activity Relationship; Thienamycins | 2018 |
A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Half-Life; Lactams; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Penicillin-Binding Proteins; Pseudomonas aeruginosa; Siderophores | 2020 |
A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Klebsiella pneumoniae; Lactams; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Siderophores; Structure-Activity Relationship | 2021 |
In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Ceftazidime; Doripenem; Humans; Imipenem; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Thienamycins; Urinary Tract Infections | 2002 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
Topics: Alanine; Animals; Anti-Bacterial Agents; Anticonvulsants; Carbapenems; Convulsants; Dogs; Doripenem; Drug Interactions; Electroencephalography; Injections, Intravenous; Injections, Intraventricular; Male; Meropenem; Mice; Mice, Inbred ICR; Pentylenetetrazole; Rats; Rats, Wistar; Seizures; Thienamycins; Valproic Acid | 2006 |
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Colony Count, Microbial; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Gene Expression; Imipenem; Meropenem; Molecular Weight; Mutation; Pseudomonas aeruginosa; Thienamycins | 2006 |
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Cilastatin; Disease Models, Animal; Doripenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Biological; Thienamycins | 2008 |
[Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Meropenem; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2007 |
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2009 |
Lucasti et al in the May 2008 issue of Clinical Therapeutics.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Thienamycins | 2008 |
In vitro activity of doripenem.
Topics: Anti-Bacterial Agents; Carbapenems; Culture Media; Doripenem; Drug Therapy, Combination; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2009 |
Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Doripenem; Drug Utilization; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Statistics as Topic; Thienamycins | 2009 |
Stability of meropenem and doripenem solutions for administration by continuous infusion.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Stability; Humans; Infusions, Intravenous; Meropenem; Solutions; Thienamycins | 2010 |
Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
Topics: Acinetobacter baumannii; beta-Lactamases; Carbapenems; Doripenem; Genotype; Hospitals; Humans; Imipenem; Meropenem; Oxytocin; Polymerase Chain Reaction; Thienamycins | 2010 |
Stability of doripenem, imipenem and meropenem at elevated room temperatures.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Stability; Drug Storage; Imipenem; Meropenem; Temperature; Thienamycins; Time Factors | 2011 |
[Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas Infections; Spain; Thienamycins | 2010 |
Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Carbapenems; Disease Models, Animal; Doripenem; Female; Imipenem; Infusions, Intravenous; Lung; Meropenem; Plasma; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Spleen; Thienamycins; Treatment Outcome | 2010 |
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
Topics: Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins | 2010 |
Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Korea; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Thienamycins; Urinary Tract Infections | 2011 |
In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Male; Meropenem; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Specific Pathogen-Free Organisms; Thienamycins | 2011 |
Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; Carbapenems; Cytokines; Disease Models, Animal; Doripenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Treatment Outcome | 2011 |
Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Topics: Anti-Bacterial Agents; Asia; Australia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Injections, Intravenous; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Thienamycins | 2011 |
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Doripenem; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Genotype; Hospitals, Urban; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phylogeny; Polymerase Chain Reaction; Sensitivity and Specificity; Thienamycins; United States | 2011 |
Comparative activity of carbapenem testing: the COMPACT study.
Topics: Africa; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle East; Thienamycins | 2011 |
Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Rectum; Stenotrophomonas maltophilia; Thienamycins | 2011 |
The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Edetic Acid; Humans; Imipenem; Laboratories; Meropenem; Microbial Sensitivity Tests; Netherlands; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Thienamycins | 2011 |
[Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Turkey | 2011 |
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Plasmids; Population Surveillance; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Spain; Thienamycins | 2011 |
Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Genotype; Imipenem; Klebsiella pneumoniae; Longitudinal Studies; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins; United States | 2011 |
Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii-calcoaceticus complex.
Topics: Acinetobacter baumannii; Acinetobacter calcoaceticus; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Streptococcus pneumoniae; Thienamycins | 2011 |
Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Humans; Imipenem; Lung; Meropenem; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Thienamycins; Treatment Outcome | 2012 |
Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Reference Standards; Thienamycins | 2012 |
Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Topics: Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Germany; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quality Control; Thienamycins | 2012 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Topics: Animals; beta-Lactams; Carbapenems; Cell Line; Doripenem; Ertapenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Salmonella; Thienamycins | 2012 |
OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem.
Topics: beta-Lactamases; Biocatalysis; Carbapenems; Cloning, Molecular; DNA Transposable Elements; Doripenem; Drug Resistance, Bacterial; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Meropenem; Models, Molecular; Plasmids; Thienamycins | 2013 |
Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Taiwan; Thienamycins | 2012 |
Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins; Time Factors | 2013 |
[Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Multiplex Polymerase Chain Reaction; Rectum; Sensitivity and Specificity; Thienamycins; Time Factors | 2012 |
Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Carbapenems; Doripenem; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Poland; Pseudomonas; Species Specificity; Sputum; Thienamycins | 2012 |
Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
Topics: Acinetobacter; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Monobactams; Pseudomonas aeruginosa; Thiazoles; Thienamycins | 2013 |
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
Topics: Adolescent; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Carbapenems; Child; Cystic Fibrosis; Disease Progression; Doripenem; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas stutzeri; Rhodospirillaceae; Thienamycins; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2013 |
In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
Topics: Acinetobacter baumannii; Bacterial Infections; Carbapenems; Doripenem; Electrophoresis, Gel, Pulsed-Field; Europe; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sensitivity and Specificity; Species Specificity; Thienamycins; United States; United States Food and Drug Administration | 2013 |
IMP-43 and IMP-44 metallo-β-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Hydrophobic and Hydrophilic Interactions; Imipenem; Japan; Meropenem; Phylogeny; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Thienamycins | 2013 |
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Topics: Antitubercular Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Wall; Clavulanic Acid; Doripenem; Enzyme Assays; Ertapenem; Escherichia coli; Gene Expression; Imipenem; Kinetics; Meropenem; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Recombinant Proteins; Thienamycins | 2013 |
Molecular epidemiology of NDM-1-producing Enterobacteriaceae and Acinetobacter baumannii isolates from Pakistan.
Topics: Acinetobacter baumannii; Amdinocillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; DNA, Bacterial; Doripenem; Enterobacteriaceae; Fosfomycin; Humans; Meropenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Pakistan; Thienamycins | 2014 |
[A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Topics: Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2014 |
Kinetic and structural requirements for carbapenemase activity in GES-type β-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Ertapenem; Escherichia coli; Kinetics; Meropenem; Models, Molecular; Thienamycins | 2015 |
[Pharmacokinetics study of injected doripenemin healthy volunteers].
Topics: Carbapenems; Chromatography, High Pressure Liquid; Doripenem; Healthy Volunteers; Humans; Infusions, Intravenous; Meropenem; Thienamycins | 2015 |
Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Computer Simulation; Doripenem; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Computer-Assisted; Female; Humans; Kidney; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Pneumonia, Bacterial; Prospective Studies; Software; Thienamycins; Treatment Outcome | 2015 |
Profiling of β-lactam selectivity for penicillin-binding proteins in Streptococcus pneumoniae D39.
Topics: Amdinocillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Doripenem; Electrophoresis, Polyacrylamide Gel; Meropenem; Penicillin-Binding Proteins; Streptococcus pneumoniae; Thienamycins | 2015 |
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Doripenem; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Rifampin; Thienamycins | 2015 |
IMP-51, a novel IMP-type metallo-β-lactamase with increased doripenem- and meropenem-hydrolyzing activities, in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate.
Topics: beta-Lactamases; Carbapenems; Cefoxitin; Doripenem; Escherichia coli; Meropenem; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa; Thienamycins | 2015 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illness; Doripenem; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Gentamicins; Lipopeptides; Meropenem; Models, Theoretical; Sheep; Sheep, Domestic; Thienamycins; Vancomycin | 2015 |
Association of doripenem resistance with OXA-type carbapenemases in Acinetobacter baumannii isolates.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Retrospective Studies; Thienamycins | 2016 |
[Analysis of carbapenems by hydrophilic interaction chromatography and its application].
Topics: beta-Lactams; Carbapenems; Chromatography; Doripenem; Drinking Water; Ertapenem; Humans; Hydrophobic and Hydrophilic Interactions; Meropenem; Thienamycins | 2015 |
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
Structural Insights into Recognition of Hydrolyzed Carbapenems and Inhibitors by Subclass B3 Metallo-β-Lactamase SMB-1.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; beta-Lactamases; Captopril; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Imipenem; Meropenem; Mesna; Protein Structure, Secondary; Protein Structure, Tertiary; Serratia marcescens; Thienamycins | 2016 |
Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Iran; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2016 |
Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Thienamycins; Treatment Outcome | 2016 |
In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Taiwan; Thienamycins | 2016 |
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Critical Care; Doripenem; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Gene Expression; Genotype; Humans; Imipenem; Klebsiella; Klebsiella Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Thienamycins; United States | 2017 |
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2017 |
Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Topics: beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Reagent Strips; Sensitivity and Specificity | 2018 |
Role of the Hydrophobic Bridge in the Carbapenemase Activity of Class D β-Lactamases.
Topics: Acinetobacter baumannii; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Doripenem; Drug Resistance, Bacterial; Imipenem; Meropenem; Microbial Sensitivity Tests; Protein Conformation | 2019 |
lptG contributes to changes in membrane permeability and the emergence of multidrug hypersusceptibility in a cystic fibrosis isolate of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; ATP-Binding Cassette Transporters; Cell Membrane; Codon, Nonsense; Cystic Fibrosis; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Humans; Imipenem; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests; Mutation, Missense; Permeability; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Whole Genome Sequencing | 2019 |
Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia.
Topics: Acinetobacter baumannii; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Female; Hospitals; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Regression Analysis; Retrospective Studies; Taiwan | 2019 |
Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Hydrophobic and Hydrophilic Interactions; Imipenem; Meropenem; Microbial Sensitivity Tests; Protein Structure, Secondary | 2019 |
In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli.
Topics: Acinetobacter baumannii; Administration, Intravenous; Animals; Anti-Bacterial Agents; Biofilms; Colistin; Disease Models, Animal; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Monte Carlo Method; Sulbactam; Treatment Outcome; Urinary Tract Infections | 2020 |
[Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Doripenem; Drug Therapy, Combination; Female; Humans; Incidence; Logistic Models; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk; Vancomycin | 2019 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia - Authors' reply.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Pseudomonas Aeruginosa as the Main Causative Agent of Osteomyelitis and its Susceptibility to Antibiotics.
Topics: Amikacin; Anti-Bacterial Agents; Chronic Disease; Doripenem; Gentamicins; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
Antimicrobial susceptibility and prevalence of resistance genes in Bacteroides fragilis isolated from blood culture bottles in two tertiary care hospitals in Japan.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Proteins; Bacteroides fragilis; Bacteroides Infections; beta-Lactamases; Blood Culture; DNA Transposable Elements; Doripenem; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Humans; Imipenem; Japan; Meropenem; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Piperacillin, Tazobactam Drug Combination; Prevalence; Sulbactam; Tertiary Care Centers | 2020 |
Molecular docking, dynamics and free energy analyses of
Topics: Acinetobacter baumannii; Ampicillin; beta-Lactamases; Carbapenems; Catalytic Domain; Computer Simulation; Doripenem; Ertapenem; Hydrolysis; Meropenem; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation | 2020 |
A method to quantify viable carbapenem resistant gram-negative bacteria in treated and untreated wastewater.
Topics: Anti-Bacterial Agents; Bacterial Load; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Ertapenem; Imipenem; Meropenem; Wastewater; Water Purification | 2020 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Association between Antimicrobial Consumption and the Prevalence of Nosocomial Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae in a Tertiary Hospital in Northern Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross Infection; Doripenem; Escherichia coli; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Prevalence; Retrospective Studies; Taiwan; Tertiary Care Centers | 2022 |
In vitro models to detect in vivo bile acid changes induced by antibiotics.
Topics: Animals; Anti-Bacterial Agents; Bile Acids and Salts; Caco-2 Cells; Colistin; Doripenem; Humans; Meropenem; Rats; RNA, Ribosomal, 16S; Taurocholic Acid; Tobramycin | 2022 |
Carbapenem resistance gene crisis in A. baumannii: a computational analysis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Doripenem; Imipenem; Meropenem; Molecular Docking Simulation | 2022 |
UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Continuous Renal Replacement Therapy; Doripenem; Humans; Levofloxacin; Linezolid; Meropenem; Tandem Mass Spectrometry | 2023 |
Molecular docking and dynamic approach to screen the drug candidate against the Imipenem-resistant CarO porin in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Porins | 2023 |
Risk evaluation of carbapenem-induced liver injury based on machine learning analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Chemical and Drug Induced Liver Injury, Chronic; Doripenem; Humans; Meropenem | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |